Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial

IMPORTANCE: The antiviral activity and efficacy of anti-SARS-CoV-2 monoclonal antibody (mAb) therapies to accelerate recovery from COVID-19 is important to define. OBJECTIVE: To determine safety and efficacy of the mAb bamlanivimab to reduce nasopharyngeal (NP) SARS-CoV-2 RNA levels and symptom dura...

Descripción completa

Detalles Bibliográficos
Autores principales: Chew, Kara W., Moser, Carlee, Daar, Eric S., Wohl, David A., Li, Jonathan Z., Coombs, Robert, Ritz, Justin, Giganti, Mark, Javan, Arzhang Cyrus, Li, Yijia, Malvestutto, Carlos, Klekotka, Paul, Price, Karen, Nirula, Ajay, Fischer, William, Bala, Veenu, Ribeiro, Ruy M., Perelson, Alan S., Fletcher, Courtney V., Eron, Joseph J., Currier, Judith S., Hughes, Michael D., Smith, Davey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722620/
https://www.ncbi.nlm.nih.gov/pubmed/34981077
http://dx.doi.org/10.1101/2021.12.17.21268009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722620/
https://www.ncbi.nlm.nih.gov/pubmed/34981077
http://dx.doi.org/10.1101/2021.12.17.21268009

Ejemplares similares